HLX43 for advanced gynecological cancers
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced cervical cancer (squamous cell, adenocarcinoma, or adenosquamous type) that has progressed after standard therapy, OR you have advanced ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum-based chemotherapy.
- You have at least one tumor that can be measured on a scan.
- You are willing to provide a tumor tissue sample for PD-L1 testing if possible.
- You have not had certain other cancers in the last 2 years, and you do not have uncontrolled heart, lung, or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug (HLX43) for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests a new drug, HLX43, for people with advanced esophageal squamous cell carcinoma that has stopped responding to or cannot tolerate standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.